• Publications
  • Influence
The Protective Role of HLA-DRB1∗13 in Autoimmune Diseases
Although different alleles were associated with particular AIDs, the same allele, HLA-DRB1∗13, was underrepresented in all of the six diseases analysed, suggesting that this allele may confer protection for AID, particularly for systemic and rheumatic disease.
Superficial cutaneous leiomyosarcoma of the face: Report of three cases
Three cases of superficial cutaneous leiomyosarcoma on the head are reported, one localized on the face and two on the forehead.
Levels of Physical Activity in Patients with Severe Psoriasis: A Cross-Sectional Questionnaire Study
The lack of physical activity may contribute to the increased risk of cardiovascular disease in Psoriasis patients, in addition to the intrinsic risks related to systemic inflammation and psoriasis-linked comorbidities.
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Current data on the impact of JAK inhibitors in the treatment of adult patients with moderate-to-severe psoriasis is reviewed.
Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib
Data from phase II and III trials are encouraging, revealing that JAK1 inhibitors are effective and well-tolerated agents for moderate-to-severe atopic dermatitis.
Plexiform schwannoma of the lip mucosa
Physicians and dentists who treat problems of the oral cavity should be aware of the need for early diagnosis of oral melanomas and the performance of biopsies of suspicious pigmented lesions.
Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis
  • T. Torres, L. Puig
  • Medicine
    American Journal of Clinical Dermatology
  • 1 February 2018
Apremilast is an oral, small-molecule phosphodiesterase 4 inhibitor that works intracellularly by blocking the degradation of cyclic adenosine 3′,5′-monophosphate, resulting in increased intrACEllular cyclicAdenosine3′, 5′-Monophosphates levels in phosphodiesters, providing apremilasts with an anti-inflammatory rather than immunosuppressive mode of action.
A revolutionary therapeutic approach for psoriasis: bispecific biological agents
Psoriasis is a chronic inflammatory skin disorder affecting 2.5% of the population worldwide.Its pathogenic mechanism involves tissue cells, in particular keratinocytes, and a wide array of immune ...
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
In this international moderate-severe psoriasis case series, biologics use was associated with lower risk of COVID-19-related hospitalization than non-biologic systemic therapies, however further investigation is warranted due to potential selection bias and unmeasured confounding.